Ignite Creation Date:
2024-05-06 @ 2:24 AM
Last Modification Date:
2024-10-26 @ 11:17 AM
Study NCT ID:
NCT02034110
Status:
COMPLETED
Last Update Posted:
2023-08-21
First Post:
2013-12-05
Brief Title:
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Cancer |
Keywords:
| Name | View |
|---|---|
| solid tumors | View |
| anaplastic thyroid cancer ATC | View |
| biliary tract cancer BTC | View |
| gastrointestinal stromal tumor GIST | View |
| low grade WHO G1G2 glioma LGG | View |
| high grade WHO G3G4 glioma HGG | View |
| non-seminomatous germ cell tumors NSGCTnon-germinomatous germ cell tumors NGGCT | View |
| adenocarcinoma of the small intestine ASI | View |
| hairy cell leukemia HCL | View |
| multiple myeloma MM | View |
| efficacy | View |
| safety | View |
| BRAF V600E mutation | View |
| Trametinib | View |
| Dabrafenib | View |